Celltrion, LISCure Biosciences to develop microbiome therapy for Parkinson's disease
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
Celltrion announced on Friday that the company has signed a joint research and development contract with LISCure Biosciences for a microbiome-based Parkinson's disease treatment.
LISCure Biosciences is a Pangyo-based biotech company that conducts research for microbiome-based treatment for Parkinson's disease. The biotech currently has an oral microbiome drug development pipeline for Parkinson's disease, called LB-P4.
Under the contract, the two companies aim to co-develop live bio-therapeutic products, or LBPs, for Parkinson's disease, Celltrion said. LBPs are biological medicinal products which consist of microorganisms.
Celltrion will provide LISCure Biosciences with research funds, while LISCure Biosciences will be responsible for the initial development stage. Celltrion will also be in charge of clinical trials and regulatory approvals.
The latest partnership comes as Celltrion aims to expand its pipeline with microbiome-based treatments, which can address a wide range of unmet medical needs. Celltrion is also looking into opportunities to add new drug pipelines for neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease.
According to GlobalData, a market research company, the global market for Parkinson's disease treatment is expected to post an annual growth rate of 12.6 percent to expand to $11.5 billion in 2029, from $3.5 billion in 2019.
"We will continue to seek open innovation opportunities with biotech companies with technological capabilities and do our best to discover new drug development pipelines,” Celltrion said.
By Shim Woo-hyun(ws@heraldcorp.com)
Copyright © 코리아헤럴드. 무단전재 및 재배포 금지.